Monitor for Phase III MAVERIC top-line data, which is the next major catalyst. The publication increases clinical credibility, but full results are needed for regulatory submission.
Price Chart
Executive Summary
Cardiol Therapeutics announced that its Phase II MAvERIC results for CardiolRx in recurrent pericarditis were accepted for publication in the Journal of the American Heart Association, providing independent validation of the clinical data. The ongoing Phase III MAVERIC trial has surpassed 75% enrollment, de-risking the program and supporting the potential for a paradigm shift in treatment.
Key Facts
- Phase II MAvERIC results accepted for publication in JAHA.
- Phase III MAVERIC trial surpassed 75% enrollment.
- CardiolRx has FDA Orphan Drug Designation for pericarditis.
- No financial figures disclosed in the filing.
Financial Impact
No direct financial impact; clinical milestone that supports pipeline value for a pre-revenue biotech.
Risk Factors
- Phase III trial failure or underwhelming results.
- Regulatory hurdles for NDA submission.
- Competition from existing immunosuppressive therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001279569-26-000398 |
| Document: cardiol6k.htm | 0001279569-26-000398 |
| Document: 0001279569-26-000398-index-headers.html | 0001279569-26-000398 |
| Document: 0001279569-26-000398-index.html | 0001279569-26-000398 |
| Document: 0001279569-26-000398.txt | 0001279569-26-000398 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | SC 13G/A | $1.77 | awaiting T+60 | — | $1.15 (−35.03%) |
Sep 23, 2026 4w ago | 6-K | $1.77 | awaiting T+60 | — | $1.15 (−35.03%) |
Sep 16, 2026 5w ago | 6-K | $1.90 | awaiting T+60 | — | $1.15 (−39.47%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.15 (−42.36%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.15 (−42.36%) |
Sep 9, 2026 6w ago | 6-K | $2.29 | awaiting T+60 | — | $1.15 (−49.67%) |
Aug 5, 2026 11w ago | 6-K | $1.34 | awaiting T+60 | — | $1.15 (−14.18%) |
Jul 14, 2026 15w ago | 6-K | $1.15 $1.32 | ▲ +14.78% | ▲ +11.41% | $1.15 (−0.00%) |
Jul 9, 2026 15w ago | 6-K | $0.9920 $1.41 | ▲ +42.14% | ▲ +40.50% | $1.15 (+15.93%) |
May 26, 2026 22w ago | 6-K | $1.30 $1.96 | ▲ +50.77% | ▲ +48.04% | $1.15 (−11.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers